In Brief: Theragenics/J&J
This article was originally published in The Gray Sheet
Executive Summary
Theragenics/J&J: Firms ink letter of intent to give Johnson & Johnson's Indigo Medical unit exclusive worldwide marketing rights to Theragenics' TheraSeed Palladium-103 implant for treatment of prostate cancer. "The initial term of the agreement is seven years with automatic extensions of three years each as long as certain performance criteria are met," Theragenics states in a release. J&J will take a $5 mil. stake in the Norcross, Georgia firm following execution of a definitive marketing agreement...